Dave CV, Kim SC, Goldfine AB, Glynn RJ, et al. Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of
SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy. Circulation 2020 Dec 11. doi: 10.1161/CIRCULATIONAHA.120.047965.
PMID: 33302723